ZTS Stock Analysis: Buy, Sell, or Hold?
ZTS - ZOETIS INC.
$77.59
1.20 (1.57%)
▲
5d:
-2.38%
30d:
-31.14%
90d:
-38.4%
BUY
HIGH Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Smart Money Accumulation
None View Scanner →
Strength: 10.0/10
Get Alerted When ZTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called ZTS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ZTS trading at deep discount. Market pricing in -13.4% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: ZTS trading at deep discount. Market pricing in -13.4% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$158.77
Based on 5.9% avg growth
INTRINSIC VALUE TODAY
$98.58
21.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZTS is currently trading at $77.59, which is considered slightly low relative to its 30-day fair value range of $72.61 to $105.66. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.4) compared to its historical average (16.1). Remarkably, the market is currently pricing in an annual earnings decline of 13.4% over the next few years. This pessimistic expectation contrasts with the company's recent 6.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ZTS is in a strong downtrend. Immediate support is located at $74.87, while resistance sits at $82.34.
Market Sentiment: ZTS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $124.59 (+60.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZTS is in a strong downtrend. Immediate support is located at $74.87, while resistance sits at $82.34.
Market Sentiment: ZTS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $124.59 (+60.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$72.61 -
$105.66
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 60.6% below Wall St target ($124.59)
Trading Range Analysis
30-Day Trading Range
$72.61 -
$105.66
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$74.87
Resistance Level
$82.34
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.45
Wall Street Target
$124.59
(+60.6%)
Revenue Growth (YoY)
2.9%
Earnings Growth (YoY)
6.0%
Profit Margin
28.0%
Valuation Discount vs History
-13.4% cheaper
PE vs Historical
10.5 vs 16.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.4%
(market-implied from PE analysis)
1-Year Target
$69.83
(-10%)
2-Year Target
$62.85
(-19%)
3-Year Target
$56.56
(-27%)
3-Yr Target (if PE normalizes)
(PE: 10→16)
$87.14
(+12%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 7.7%)
$202.98
(+162%)
Base:
(SPY PE: 10.5, Growth: 7.7%)
$96.82
(+25%)
Bear:
(PE: 8.9, Growth: 7.7%)
$82.30
(+6%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 13.03 | Current EPS (TTM): $6.10
Bull Case
$106.53
(+36%)
Analyst growth 21.9%, PE expands to 14.3
Base Case
$96.85
(+24%)
Market implied 21.9%, PE stable at 13.0
Bear Case
$54.05
(-31%)
Severe decline -20.0%, PE contracts to 11.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.5 to 16.1
Stabilization Target:
$119.53
(+54.1%)
PE Expansion Potential:
+54.1%
Share & Embed Analysis
Last updated: June 04, 2026 1:14 AM ET
Data refreshes hourly during market hours. Next update: 2:14 AM
Data refreshes hourly during market hours. Next update: 2:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZTS showing a specific setup today?
Insider Activity (6 Months)
4
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Gilbert Ray Cisneros, Jr.
SELL
2026-03-13
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$192 | 66 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 56 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 55 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
Advanced ZTS Option Strategies
Professional options setups generated by AI based on today's ZTS price and gamma walls.
